Open AccessApoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor
Author(s) -
Nozomu Murai,
Tetsuya Ueba,
J. Takahashi,
Haonan Yang,
Hiroe Kikuchi,
Hiroshi Hayashi,
Masakazu Hatanaka,
Manabu Fukumoto
Publication year - 1996
Publication title -
journal of neurosurgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.564
H-Index - 210
eISSN - 1933-0693
pISSN - 0022-3085
DOI - 10.3171/jns.1996.85.6.1072
Subject(s) - basic fibroblast growth factor , glioma , cancer research , autocrine signalling , apoptosis , monoclonal antibody , in vivo , growth factor , biology , cell culture , microbiology and biotechnology , antibody , immunology , receptor , biochemistry , genetics
✓ Basic fibroblast growth factor (bFGF) is mitogenic to neuroectoderm- and mesoderm-derived cells and is a potent angiogenic factor. Abundant amounts of this factor and its receptor are detected in human glioma tissues and cells, and bFGF in glioma is thought to be involved in autonomous cell growth as an autocrine growth factor. A neutralizing mouse monoclonal antibody (MAb) against bFGF, 3H3 MAb, has been shown to inhibit both in vitro and in vivo growth of human glioma cell lines. This study shows that the human glioma cell lines U-87MG and U-251MG, which express high levels of bFGF and its receptor, can be induced to undergo apoptosis when cultured with 3H3 MAb. It is also demonstrated that 3H3 MAb can cause apoptosis in the same glioma cells that were transplanted into nude mice. Furthermore, enforced overexpression of bcl-2 protein by gene transfection prevented 3H3 MAb-induced apoptosis of glioma cells. It is concluded that induction of apoptosis by the neutralizing antibody is a promising therapeutic strategy for glioma.